AEGLEA BIOTHERAPEUTICS INC's ticker is AGLE and the CUSIP is 00773J103. A total of 94 filers reported holding AEGLEA BIOTHERAPEUTICS INC in Q4 2020. The put-call ratio across all filers is - and the average weighting 0.2%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q1 2022 | $246,000 | -48.0% | 106,810 | +7.4% | 0.00% | – |
Q4 2021 | $473,000 | -40.2% | 99,477 | 0.0% | 0.00% | – |
Q3 2021 | $791,000 | +7.3% | 99,477 | -6.0% | 0.00% | – |
Q2 2021 | $737,000 | -16.1% | 105,779 | -4.5% | 0.00% | – |
Q1 2021 | $878,000 | -0.8% | 110,783 | -1.5% | 0.00% | – |
Q4 2020 | $885,000 | +18.0% | 112,424 | +6.4% | 0.00% | – |
Q3 2020 | $750,000 | -25.5% | 105,653 | -2.9% | 0.00% | – |
Q2 2020 | $1,007,000 | +255.8% | 108,846 | +79.7% | 0.00% | – |
Q1 2020 | $283,000 | -37.9% | 60,560 | +1.6% | 0.00% | – |
Q4 2019 | $456,000 | -0.7% | 59,621 | 0.0% | 0.00% | – |
Q3 2019 | $459,000 | +12.2% | 59,621 | 0.0% | 0.00% | – |
Q2 2019 | $409,000 | +13.9% | 59,621 | +33.9% | 0.00% | – |
Q1 2019 | $359,000 | +16.2% | 44,511 | +8.1% | 0.00% | – |
Q4 2018 | $309,000 | +6.6% | 41,160 | +35.8% | 0.00% | – |
Q3 2018 | $290,000 | -9.7% | 30,300 | 0.0% | 0.00% | – |
Q2 2018 | $321,000 | – | 30,300 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
UNIVERSITY OF TEXAS/TEXAS AM INVESTMENT MANAGEMENT CO | 279,678 | $2,587,000 | 10.00% |
Aisling Capital Management LP | 1,691,151 | $15,643,000 | 5.97% |
Samsara BioCapital, LLC | 967,500 | $8,949,000 | 2.88% |
Bain Capital Life Sciences Investors, LLC | 2,700,000 | $24,975,000 | 2.62% |
Soleus Capital Management, L.P. | 369,852 | $3,421,000 | 1.95% |
Nantahala Capital Management | 3,204,830 | $29,645,000 | 0.89% |
Lion Point Capital, LP | 300,000 | $2,775,000 | 0.67% |
Abingworth LLP | 240,500 | $2,221,000 | 0.62% |
Sio Capital Management, LLC | 211,104 | $1,953,000 | 0.57% |
Orbimed Advisors | 4,015,524 | $37,144,000 | 0.52% |